<DOC>
	<DOC>NCT00144131</DOC>
	<brief_summary>This study will compare the efficacy (non-inferiority) of darbepoetin alfa (Aranesp®) extended dose schedule administration (EDS) versus darbepoetin alfa administered once per week (QW) in the treatment of anemia in subjects with non-myeloid malignancies receiving multi-cycle chemotherapy.</brief_summary>
	<brief_title>Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects with active nonmyeloid malignancy(ies) including lymphocytic leukemias Receiving chemotherapy and expected to receive at least 8 additional weeks of cyclic cytotoxic chemotherapy anticipated to be on a QW, every other week (Q2W) or every three weeks (Q3W) schedule Anemia due to cancer and/or chemotherapy (screening Hb less than 11.0 g/dL) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or myelodysplastic syndromes (MDS) Other underlying hematologic disorder, which could cause anemia, other than a nonmyeloid malignancy Active bleeding Severe, unstable, active chronic inflammatory disease (e.g., ulcerative disease, peptic ulcer disease, rheumatoid arthritis) Active, unstable systemic or chronic infection Planned elective surgery during the study where significant blood loss is expected Known iron deficiency (to be considered iron deficient a subject must have both of the following: a saturated transferrin less than 15% and ferritin less than 10 ng/mL at screening) Unstable angina, or uncontrolled cardiac arrhythmia Hypertension (diastolic blood pressure greater than 100 mmHg) Inadequate renal and/or liver function (e.g., creatinine greater than 2 X upper limit of normal (ULN) and/or transaminase greater than 5 X ULN) History of pure red blood cell aplasia Known positive human immunodeficiency virus (HIV) test or acquired immune deficiency syndrome (AIDS) status Known positive antibody response to any erythropoietic agent Subject has known sensitivity to any erythropoietic agents, the study drug, or its excipients to be administered during this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Chemotherapy, Anemia</keyword>
	<keyword>Aranesp®, rHuEPO</keyword>
	<keyword>Chemotherapy Induced Anemia</keyword>
	<keyword>non-myeloid malignancy</keyword>
	<keyword>Non-Myeloid Malignancies</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>